CBD (Cannabidiol) for Alzheimer's Disease Agitation - NCT06014424

Migration, Crosslink

📖

CBD (Cannabidiol) for Alzheimer's Disease Agitation - NCT06014424

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-nct06014424-cbd-alz

📖 Wiki Page

clinical2012 wordssynced 2026-04-02

Overview

flowchart TD clinical_trials_nct06014424_cb["CBD Cannabidiol for Alzheimers Disease Agitat"] style clinical_trials_nct06014424_cb fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_nct0_0["Trial Details"] clinical_trials_nct06014424_cb -->|"includes"| clinical_trials_nct0_0 style clinical_trials_nct0_0 fill:#81c784,stroke:#333,color:#000 clinical_trials_nct0_1["Background: Agitation in Alzheimers Disease"] clinical_trials_nct06014424_cb -->|"includes"| clinical_trials_nct0_1 style clinical_trials_nct0_1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_nct0_2["Definition and Prevalence"] clinical_trials_nct06014424_cb -->|"includes"| clinical_trials_nct0_2 style clinical_trials_nct0_2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_nct0_3["Impact on Caregiving"] clinical_trials_nct06014424_cb -->|"includes"| clinical_trials_nct0_3 style clinical_trials_nct0_3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_nct0_4["Current Treatment Landscape"] clinical_trials_nct06014424_cb -->|"includes"| clinical_trials_nct0_4 style clinical_trials_nct0_4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_nct0_5["Study Description"] clinical_trials_nct06014424_cb -->|"includes"| clinical_trials_nct0_5 style clinical_trials_nct0_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

NCT06014424 is a Phase 2 clinical trial investigating the efficacy of cannabidiol (CBD) for managing agitation in [Alzheimer's disease](/diseases/alzheimers-disease) patients. The study is conducted at Sunnybrook Health Sciences Centre in Toronto, Canada, representing a significant investigation into non-psychotropic cannabinoid therapy for behavioral symptoms in neurodegenerative disease["@agganci2019"].

Agitation represents one of the most challenging aspects of Alzheimer's disease care, affecting approximately 50-80% of patients at some point during disease progression. This symptom significantly impacts quality of life for both patients and caregivers, often leading to institutionalization and increased healthcare costs.

Trial Details

| Attribute | Value |
|-----------|-------|
| NCT ID | NCT06014424 |
| Phase | Phase 2 |
| Status | Recruiting |
| Study Type | Interventional |
| Design | Cross-over trial |
| Intervention | CBD capsules |
| Indication | Agitation in Alzheimer's Disease |
| Sponsor | Sunnybrook Health Sciences Centre |
| Location | Toronto, Ontario, Canada |

Background: Agitation in Alzheimer's Disease

Definition and Prevalence

Agitation in dementia encompasses a spectrum of behaviors including restlessness, pacing, verbal aggression, physical aggression, and disinhibition. According to the Cohen-Mansfield Agitation Inventory (CMAI), these behaviors are categorized into physically non-aggressive behaviors (pacing, inappropriate robing), verbally aggressive behaviors (screaming, complaining), and physically aggressive behaviors (hitting, kicking)[@egaert2019].

The prevalence of agitation increases with disease severity:

Mild AD: 30-40% experience agitation
Moderate AD: 50-60% experience agitation
Severe AD: 70-80% experience agitation

Impact on Caregiving

Agitation is a leading cause of caregiver burnout and institutionalization:

Caregiver stress: Constant vigilance and management of agitation leads to physical and emotional exhaustion

Safety concerns: Aggressive behaviors pose risks to both patient and caregiver

Economic burden: Behavioral symptoms account for up to 40% of dementia care costs

Quality of life: Agitation significantly diminishes quality of life for patients and families

Current Treatment Landscape

Non-pharmacological approaches are first-line treatment:

Environmental modifications
Music therapy
Pet therapy
Structured activities
Caregiver education

Pharmacological options are limited and often suboptimal:

Antipsychotics: Black box warning for increased mortality
Benzodiazepines: Risk of sedation, falls, cognitive worsening
Antidepressants: Variable efficacy, side effects
Acetylcholinesterase inhibitors: Modest benefit for some patients

This underscores the urgent need for novel therapeutic approaches with better safety profiles.

Study Description

Rationale for CBD

Cannabidiol (CBD) has emerged as a promising candidate for managing behavioral symptoms in dementia for several reasons[@watt2017]:

Non-psychotropic properties: Unlike tetrahydrocannabinol (THC), CBD does not produce psychoactive effects, making it suitable for elderly patients with cognitive impairment.

Multiple mechanisms of action: CBD interacts with numerous receptor systems implicated in agitation:

Endocannabinoid system modulation (CB1, CB2 receptors)
Serotonin 5-HT1A receptor agonism
PPAR-gamma nuclear receptor activation
TRPV1 vanilloid receptor modulation
Anti-inflammatory effects via COX-2 inhibition

Safety profile: CBD has been shown to have a favorable safety profile in clinical trials, with mild to moderate side effects including dry mouth, drowsiness, and diarrhea.

Preclinical Evidence

Several preclinical studies support CBD's potential for neurodegenerative applications[@mishra2012]:

Neuroprotection: CBD protects against amyloid-beta induced neurotoxicity in vitro
Anti-inflammatory: Reduces microglial activation and pro-inflammatory cytokines
Antioxidant: Scavenges free radicals and reduces oxidative stress
Anti-apoptotic: Prevents neuronal cell death in cellular models

Clinical Evidence

While direct clinical trial data for CBD in Alzheimer's agitation is limited, related evidence exists[@kumar2021]:

Dementia-related behaviors: Small studies show THC/CBD combinations may reduce agitation
Parkinson's disease: CBD has been studied for psychosis and motor symptoms
Epilepsy: CBD safety established in thousands of pediatric and adult patients
Anxiety: CBD demonstrates anxiolytic effects in clinical trials

Proposed Mechanism in Agitation

CBD may address agitation through multiple pathways[@cohen2022]:

Anxiolytic effects: 5-HT1A receptor agonism reduces anxiety, a common trigger for agitation

Sleep regulation: CBD may improve sleep-wake cycles disrupted in dementia

Anti-inflammatory: Neuroinflammation contributes to behavioral symptoms

Neuroprotection: May slow underlying neurodegeneration affecting behavior regulation

Study Design

Cross-over Methodology

The cross-over design offers several advantages for this trial:

Within-patient comparison: Each patient serves as their own control, eliminating inter-individual variability.

Efficient sample size: Fewer participants needed compared to parallel-group designs.

Treatment sequence: Patients receive both CBD and placebo in randomized order, with washout periods between treatments.

Blinding: Both patients and investigators are blinded to treatment allocation until trial completion.

Treatment Protocol

| Phase | Duration | Treatment |
|-------|----------|-----------|
| Baseline | 2 weeks | Screening/washout |
| Period 1 | 8 weeks | CBD or placebo |
| Washout | 2 weeks | Medication-free |
| Period 2 | 8 weeks | Alternate treatment |

Dosage Considerations

CBD dosing in clinical trials varies widely:

Low dose: 10-20 mg/day
Medium dose: 50-100 mg/day
High dose: 200-500 mg/day

The optimal dose for agitation will be determined through dose-escalation components of the trial.

Outcome Measures

Primary Endpoints

| Measure | Scale | Description |
|---------|-------|-------------|
| Agitation | CMAI | Cohen-Mansfield Agitation Inventory |
| Behavior | NPI | Neuropsychiatric Inventory |
| Response | CGI-C | Clinical Global Impression of Change |

Secondary Endpoints

Sleep quality (actigraphy, sleep diaries)
Caregiver burden (Zarit Burden Interview)
Cognitive function (MMSE, ADAS-Cog)
Safety and tolerability
Quality of life (QoL-AD)

Exploratory Endpoints

Biomarker collection (inflammatory markers)
Pharmacokinetic sampling
Adverse event monitoring

Inclusion Criteria

Key inclusion criteria:

Clinical diagnosis of Alzheimer's disease

Clinically significant agitation (CMAI score >= 25)

Age 60-90 years

Stable AD medications (if any) for >=4 weeks

Available caregiver/informant

Able to swallow capsules

Exclusion Criteria

Key exclusion criteria:

Prior cannabis use disorder

Significant liver dysfunction (elevated LFTs >3x ULN)

Current use of CBD or cannabis products

Severe medical conditions

Psychotic disorders unrelated to dementia

Contraindications to study procedures

Safety Considerations

CBD Safety Profile

CBD is generally well-tolerated with a favorable safety profile:

| Adverse Event | Frequency | Severity |
|---------------|-----------|----------|
| Drowsiness | 10-20% | Mild-moderate |
| Dry mouth | 5-15% | Mild |
| Diarrhea | 5-10% | Mild |
| Nausea | 3-8% | Mild |
| Liver enzyme elevation | 2-5% | Mild-moderate |

Drug Interactions

CBD may interact with certain medications through CYP450 enzyme inhibition:

Warfarin: May increase INR
Anticonvulsants: May alter levels
Antidepressants: May increase levels of some SSRIs
Antipsychotics: May increase levels of some agents

Special Populations

Elderly patients require careful monitoring:

Start low, go slow dosing strategy
Renal and hepatic function monitoring
Orthostatic hypotension precautions
Fall risk assessment

Clinical Implications

Potential Benefits

If successful, this trial could provide:

Novel treatment option: First evidence-based CBD formulation for AD agitation

Improved safety: Better side effect profile than antipsychotics

Natural product appeal: Patient/caregiver preference for plant-based options

Disease-modifying potential: Neuroprotective effects may slow progression

Challenges

Several challenges remain:

Variable response: Individual variability in CBD metabolism
Dosing optimization: Finding optimal dose for geriatric population
Long-term effects: Unknown effects with extended use
Regulatory status: CBD remains controlled substance in some jurisdictions

Regulatory Considerations

FDA Status

CBD products occupy a complex regulatory space:

Epidiolex (CBD for epilepsy) is FDA-approved
CBD in dietary supplements remains legally uncertain
CBD for neurological indications requires prescription

Health Canada Context

As the trial is conducted in Canada, Health Canada regulations apply:

CBD is legal for medical purposes with prescription
Product quality and consistency are regulated
Clinical trial authorization required

Endocannabinoid System in Alzheimer's Disease

The Endocannabinoid System

The endocannabinoid system (ECS) is a complex signaling network involved in numerous physiological processes[@zhorn2021]:

Components:

Endogenous cannabinoids (anandamide, 2-AG)
Cannabinoid receptors (CB1, CB2)
Metabolic enzymes (FAAH, MAGL)

Distribution:

CB1: abundant in brain (hippocampus, cortex, basal ganglia)
CB2: primarily immune cells, low in healthy brain
Both upregulated in neurodegeneration

ECS Dysfunction in AD

The ECS is altered in Alzheimer's disease:

CB1 Receptor Changes:

Reduced CB1 density in AD brains
Correlates with cognitive decline
Linked to neurotransmitter dysfunction

CB2 Receptor Upregulation:

Increased CB2 in activated microglia
Marker of neuroinflammation
Potential therapeutic target

Endocannabinoid Levels:

Elevated anandamide in AD CSF
Correlates with disease severity
Suggests compensatory mechanism

CBD Mechanisms in AD

CBD exerts multiple effects relevant to AD[@bhatt2023]:

Anti-inflammatory Effects:

Reduces microglial activation
Decreases pro-inflammatory cytokines
Modulates neuroinflammation

Neuroprotection:

Protects against amyloid toxicity
Reduces tau phosphorylation
Supports mitochondrial function

Synaptic Function[@wei2023]:

Enhances synaptic plasticity
Improves memory in models
Modulates neurotransmitter release

Clinical Trial Design Considerations

Cross-over Trial Strengths

Statistical Efficiency:

Each patient serves as their own control
Reduces inter-subject variability
Requires smaller sample size

Practical Advantages:

All patients receive active treatment
Patient preference considerations
Ethical appeal of no placebo-only group

Limitations:

Carryover effects between periods
Cannot separate treatment from time effects
May not be suitable for progressive diseases

Agitation Assessment Tools

Cohen-Mansfield Agitation Inventory (CMAI):

29-item behavioral checklist
Frequency ratings (1-7 scale)
Categories: physical/verbal aggressive, non-aggressive

Neuropsychiatric Inventory (NPI):

12 behavioral domains
Frequency and severity scoring
Caregiver distress ratings

Agitation Efficacy Scale:

Newly validated for clinical trials
Combines multiple assessment modalities

Safety and Pharmacology

CBD Pharmacokinetics

Absorption:

Oral bioavailability: 6-19%
Affected by food intake
Tmax: 2-3 hours

Distribution:

Highly protein bound
Wide tissue distribution
Crosses blood-brain barrier

Metabolism:

hepatic CYP2C19, CYP3A4
Extensive first-pass metabolism
Active metabolites

Elimination:

Half-life: 18-32 hours
Fecal excretion predominant
Terminal elimination complex

Geriatric Considerations

Elderly patients require special attention[@ibeh2022]:

Pharmacokinetic Changes:

Reduced hepatic metabolism
Decreased renal clearance
Altered protein binding

Pharmacodynamic Sensitivity:

Increased CNS sensitivity
Fall risk considerations
Cognitive effects monitoring

Dosing Strategy:

Start low (10-20 mg/day)
Slow titration
Individualized approach

Drug-Drug Interactions

CBD inhibits cytochrome P450 enzymes:

Clinically Significant Interactions:

Warfarin: Increased anticoagulation
Anticonvulsants: Altered levels
SSRI/SNRI: Serotonin syndrome risk

Monitoring Required:

Valproate levels
Clobazam levels
Tacrolimus levels

Competitive Landscape

Other CBD Trials in Dementia

Multiple studies investigating cannabinoids in dementia:

| Study | Design | Intervention | Status |
|-------|--------|--------------|--------|
| This trial | Cross-over | CBD capsules | Recruiting |
| Sativex | Parallel | THC:CBD | Completed |
| Zynerba | Parallel | CBD gel | Recruiting |

Comparison of Cannabinoid Approaches

CBD Only:

Non-psychotropic
Wide dosing range
Good safety profile

THC:CBD Combination:

Entourage effect
Psychoactive effects
Limited in elderly

Synthetic Cannabinoids:

Nabilone for agitation
Dronabinol for appetite
Limited evidence

Future Directions

Biomarker Development

Future trials may incorporate:

Inflammatory biomarkers (IL-6, TNF-α)
Neurofilament light chain
Imaging correlates

Personalized Medicine

Potential for personalized approaches:

Pharmacogenetic testing
CB2 receptor genotyping
Inflammation profiling

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Behavioral and Psychological Symptoms of Dementia](/diseases/bpsd)

[Cannabinoids in Neurodegeneration](/therapeutics/cannabinoids-neurodegeneration)
[CBD for Neurodegeneration](/therapeutics/cbd-neurodegeneration)
[Non-pharmacological Dementia Treatments](/therapeutics)

[Endocannabinoid System in Neurodegeneration](/mechanisms/endocannabinoid-system-neurodegeneration)
[Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
[Neurotransmitter Systems in Dementia](/mechanisms/neurotransmitter-systems-dementia)

External Links

[ClinicalTrials.gov - NCT06014424](https://clinicaltrials.gov/study/NCT06014424)
[Sunnybrook Health Sciences Centre](https://sunnybrook.ca/)
[Alzheimer's Association Canada](https://alzheimer.ca/)

References

[Aggarwal et al., Cannabidiol in the treatment of Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31396396/)

[Watt et al., Molecular targets of the phytocannabinoids (2017)](https://pubmed.ncbi.nlm.nih.gov/28089419/)

[Mishra et al., Cannabidiol for neurodegenerative disorders (2012)](https://pubmed.ncbi.nlm.nih.gov/22689829/)

[Egaert et al., Behavioral and psychological symptoms of dementia (2019)](https://pubmed.ncbi.nlm.nih.gov/31229142/)

[Kumar et al., THC and CBD in dementia (2021)](https://pubmed.ncbi.nlm.nih.gov/33504177/)

[Cohen et al., Cannabis derivatives for Alzheimer's (2022)](https://pubmed.ncbi.nlm.nih.gov/35004983/)

[Bhatt et al., CBD effects on neuroinflammation in AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Zhorn et al., Endocannabinoid system in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Peyravian et al., Cannabidiol as a potential treatment for anxiety (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Martinez et al., CB2 receptor and neuroinflammation (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Fernandez et al., CBD and tau pathology (2020)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Gomez et al., Neuroprotective effects of CBD (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Sandoval et al., Agitation management in dementia (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Wei et al., CBD and synaptic plasticity (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Ibeh et al., Cannabis-based medicines for dementia (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

Pathway Diagram

The following diagram shows the key molecular relationships involving CBD (Cannabidiol) for Alzheimer's Disease Agitation - NCT06014424 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

clinical-trials-nct06014424-cbd-alzheimers-agitation

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-nct06014424-cbd-alzheimers-agitation
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-7c47fdf794c8
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-nct06014424-cbd-alzheimers-agitation'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

513

Outgoing

532

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CBD (Cannabidiol) for Alzheimer's Disease Agitation - NCT06014424

Overview

Overview

Trial Details

Background: Agitation in Alzheimer's Disease

Definition and Prevalence

Impact on Caregiving

Current Treatment Landscape

Study Description

Rationale for CBD

Preclinical Evidence

Clinical Evidence

Proposed Mechanism in Agitation

Study Design

Cross-over Methodology

Treatment Protocol

Dosage Considerations

Outcome Measures

Primary Endpoints

Secondary Endpoints

Exploratory Endpoints

Inclusion Criteria

Exclusion Criteria

Safety Considerations

CBD Safety Profile

Drug Interactions

Special Populations

Clinical Implications

Potential Benefits

Challenges

Regulatory Considerations

FDA Status

Health Canada Context

Endocannabinoid System in Alzheimer's Disease

The Endocannabinoid System

ECS Dysfunction in AD

CBD Mechanisms in AD

Clinical Trial Design Considerations

Cross-over Trial Strengths

Agitation Assessment Tools

Safety and Pharmacology

CBD Pharmacokinetics

Geriatric Considerations

Drug-Drug Interactions

Competitive Landscape

Other CBD Trials in Dementia

Comparison of Cannabinoid Approaches

Future Directions

Biomarker Development

Personalized Medicine

Related Pages

Related Conditions

Related Therapeutics

Related Mechanisms

External Links

References

Pathway Diagram

💬 Discussion